Business

Healing Biotech Restructures to Join NYSE, Offers $8 Million (OTCMKTS:CUBT)


Financial term abbreviated IPO stands for Initial Public Offering on the blue block corner

DariaRen / iStock via Getty Images

Medical Biotechnology Drug Developers (OTC: CUBT) filed an application with the NYSE and conducted an $8 million public offering following its withdrawal in late October.

Florida-based bio company says in a new one Filing an S-1 that they are planning to offer 1.3 million units for $6 each, a price that is subject to change. Each unit will include one share plus a warrant to buy one share at $9.

The underwriter will be granted a 45-day call option to purchase an additional 15% of the total shares and/or warrants sold to cover any over-allocation. Aegis Capital is acting as the primary book miner.

Before the offering, Curative plans to conduct a reverse stock split of 1 to 400. The company’s shares are currently listed OTC with the symbol CUBT. It said it was approved to list under the same logo on the NYSE.

Curative is currently developing four licensed preclinical drug candidates for the treatment of rabies, glioblastoma, and age-related macular degeneration, along with one COVID-19 vaccine candidate for the disease. renal failure.

Biotechnology company First time filing S-1 for accession in April, clearly stated in next profile that they are looking to raise about $8 million. Company withdrew the S-1 on October 31.

news7f

News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button